About IHD
IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.
Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.
Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:
• Angina pectoris
• Myocardial infarction.
The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• AstraZeneca
• Bayer
• Eli Lilly
• Novartis
• Pfizer
• Sanofi
Other Prominent Vendors
• Actelion
• Amgen
• Baxter
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi-Sankyo
• Eisai
• F.Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Human Stem Cells Institute
• Janssen Pharmaceuticals
• Juventas Therapeutics
• Lacer
• Merck
• Nuo Therapeutics
• Ono Pharmaceutical
• Pharmahungary Group
• Resverlogix
• Takeda Pharmaceutical Company
• Taxus Cardium
• The Medicines Company
• United Therapeutics
Market Driver
• Rise in Number of Patients
• For a full and detailed list, view our report
Market Challenge
• Delayed Diagnosis
• For a full and detailed list, view our report
Market Trend
• Increase in Health Awareness
• For a full and detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology and Risk Factors
06.2.1 Modifiable Risk Factors
06.2.2 Non-modifiable Risk Factors
06.3 Pathophysiology
06.4 Signs and Symptoms
06.5 Diagnosis
06.5.1 ECG
06.5.2 Stress Testing
06.5.3 Echocardiography
06.5.4 Chest X-Ray
06.5.5 Blood Tests
06.5.6 Coronary Angiography and Cardiac Catheterization
06.6 Management
06.6.1 Lifestyle Changes
06.6.2 Pharmacotherapy
06.6.3 Medical Procedures
06.7 Epidemiology
06.8 Economic Burden
07. Pipeline Analysis
07.1 Information on Pipeline Candidates
07.1.1 ONO-1101
07.1.2 Ranolazine
07.1.3 Autologous CD34+ stem cells
07.1.4 Generx
07.1.5 Cryocell
07.1.6 RVX-208
07.1.7 MPSK3169A
07.1.8 GS-6615
07.1.9 JVS-100
07.1.10 LA-419
07.1.11 ALD-201
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Disease Class
09.1 Angina Pectoris
09.1.1 Stable Angina
09.1.2 Unstable Angina
09.1.3 Prinzmetal's Angina
09.2 MI
09.2.1 STEMI
09.2.2 NSTEMI
10. Market Segmentation by Drug Class
10.1 Anti-dyslipidemic Drugs
10.2 Calcium Channel Blockers
10.3 Beta-blockers
10.4 ACE Inhibitors
10.5 ARBs
10.6 Vasodilators
10.7 Antithrombotic Agents
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 AstraZeneca
19.2.2 Bayer
19.2.3 Eli Lilly
19.2.4 Novartis
19.2.5 Pfizer
19.2.6 Sanofi
19.3 Other and Future Prominent Vendors
20. Global IHD Drugs Market: Key Takeaways
21. Key Vendor Analysis
21.1 AstraZeneca plc
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2011-2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Developments
21.1.8 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Eli Lilly
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue
21.3.4 Sales by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 Novartis AG
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Pfizer
21.5.1 Key facts
21.5.2 Business overview
21.5.3 Business segmentation by revenue 2014
21.5.4 Business segmentation by revenue 2013 and 2014
21.5.5 Geographical segmentation by revenue 2014
21.5.6 Business strategy
21.5.7 Key developments
21.5.8 SWOT analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Overview of IHD
Exhibit 3: Pathophysiology of IHD
Exhibit 4: Leading Cause of Death in World 2012
Exhibit 5: Leading Cause of Death in US 2013
Exhibit 6: Pipeline Portfolio of IHD Drugs
Exhibit 7: Global IHD Drugs Market 2014-2019 ($ millions)
Exhibit 8: Global IHD Drugs Market Segment by Disease Class
Exhibit 9: Global IHD Drugs Market Segment by Drug Class
Exhibit 10: Segmentation of Global IHD Drugs Market by Geography 2014
Exhibit 11: YoY Growth and Revenue of Atacand 2010-2014 ($ millions)
Exhibit 12: YoY Growth and Revenue of Crestor 2010-2014 ($ millions)
Exhibit 13: YoY Growth and Revenue of Seloken/Toprol-XL 2010-2014 ($ millions)
Exhibit 14: YoY Growth and Revenue of Adalat 2010-2014 ($ millions)
Exhibit 15: YoY Growth and Revenue of Xarelto 2010-2014 ($ millions)
Exhibit 16: YoY Growth and Revenue of Effient 2010-2014 ($ millions)
Exhibit 17: YoY Growth and Revenue of Diovan 2010-2014 ($ millions)
Exhibit 18: YoY Growth and Revenue of Exforge 2010-2014 ($ millions)
Exhibit 19: YoY Growth and Revenue of Caduet 2010-2014 ($ millions)
Exhibit 20: YoY Growth and Revenue of Fragmin 2010-2014 ($ millions)
Exhibit 21: YoY Growth and Revenue of Lipitor 2010-2014 ($ millions)
Exhibit 22: YoY Growth and Revenue of Norvasc 2010-2014 ($ millions)
Exhibit 23: YoY Growth and Revenue of Lovenox 2010-2014 ($ millions)
Exhibit 24: YoY Growth and Revenue of Plavix 2010-2014 ($ millions)
Exhibit 25: Global IHD Drugs Market: Key Takeaways
Exhibit 26: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 ($ millions)
Exhibit 28: AstraZeneca plc: Sales by Geography 2013
Exhibit 29: Bayer: Business segmentation by revenue 2014
Exhibit 30: Bayer: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 31: Bayer: Geographical segmentation by revenue 2014
Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 34: Eli Lilly: Sales by Geography 2013
Exhibit 35: Novartis AG: Business Segmentation
Exhibit 36: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 37: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 38: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 39: Pfizer: Business segmentation by revenue 2014
Exhibit 40: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 41: Pfizer: Geographical segmentation by revenue 2014
Exhibit 42: Sanofi SA: Business Segmentation
Exhibit 43: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 44: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 45: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
